Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Consider This Before You Buy Biogen

TheMotleyFool

0 0

Biogen (NASDAQ: BIIB) is the leading maker of medicine used to treat multiple sclerosis. However, new drugs from Roche Holdings (NASDAQOTH: RHHBY) and Celgene Corp. (NASDAQ: CELG) threaten its dominance and add pressure to the company to diversify itself.

In March, Roche Holdings earned an FDA green light to begin marketing Ocrevus, a new MS therapy approved for use both in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com

Like: 0

RHHBY

Share